An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 425-433

  Brady, C M ^a   DasGupta, R ^a   Dalton, C ^a   Wiseman, O J ^a   Berkley, K J ^b   Fowler, Clare J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Cannabidiol; Cannabis; Delta 9 tetrahydrocannabinol; Multiple sclerosis; Neurogenic detrusor overactivity; Neuropathic pain; Sleep disorder; Spasticity; Urinary incontinence

Indexed keywords

CANNABIDIOL; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; DRONABINOL; OXYBUTYNIN;

ADULT; ARTICLE; AUDITORY HALLUCINATION; BLADDER CAPACITY; BLADDER DYSFUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTOMETRY; DISORIENTATION; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM CARE; MALE; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE SCLEROSIS; NEBULIZATION; NOCTURIA; OPEN STUDY; PAIN ASSESSMENT; PERCEPTION DISORDER; PILOT STUDY; SELF EVALUATION; SLEEP; SPASTICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; TREMOR; URINARY FREQUENCY; URINE INCONTINENCE; VISUAL ANALOG SCALE; VISUAL HALLUCINATION; WILCOXON SIGNED RANKS TEST; XEROSTOMIA;

ADULT; CANNABIDIOL; CANNABIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MEDICAL RECORDS; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; PLANT EXTRACTS; QUESTIONNAIRES; SENSATION; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URINATION; URODYNAMICS;

EID: 4344585483     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1063oa     Document Type: Article

References (31)

1. Koldewijn E, Hommes O, Lemmens W, Debruyne F, van Kerrebroeck P. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995; 154: 169-73.
2. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48.
3. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
4. Jaggar SI, Sellaturay S, Rice AS. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 1998; 253: 123-26.
5. Pertwee RG, Fernando SR. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 1996; 118: 2053-58.
6. Dmitrieva N, Berkley KJ. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci 2002; 22: 7147-53.
7. Martin RS, Luong LA, Welsh NJ, Eglen RM, Martin GR, MacLennan SJ. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol 2000; 129: 1707-15.
8. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative auto-radiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318.
9. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004; 59: 440-52.
10. Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Ther 2001; 1: 183-205.
11. Robson PJ, Guy GW. Clinical studies of cannabis medicines. In Cannabis and cannabinoids as medicines. London: Pharmaceutical Press, 2004.
12. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
13. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 2001; 134: 945-50.
14. Bartocci C, Evandri MG, Tucci P, Bolle P. Interactions between A-9THC and capsaicin on isolated lamb bladder detrusor. Farmaco 2001; 56: 349-51.
15. Christopoulos A, Wilson K. Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. Brain Res 2001; 915: 70-78.
16. Lagalwar S, Bordayo EZ, Hoffmann KL, Fawcett JR, Frey WH, 2nd. Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 1999; 13: 55-61.
17. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997; 121: 1557-66.
18. Wiseman OJ, Fowler CJ, Landon DN. The role of the human bladder lamina propria myofibroblast. BJU Int 2003; 91: 89-93.
19. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000; 129: 227-30.
20. Szallasi A, Fowler CJ. After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurol 2002; 1: 167-72.
21. Brady CM, Apostolidis A, Harper M, Yiangou Y, Beckett A, Jacques TS et al. Parallel changes in bladder suburothelial vanilloid receptor TPPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor over-activity (NDO) after intravesical. resiniferatoxin treatment. BJU Int 2004; 93: 770-76.
22. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189-99.
23. Athwal B, Berkley K, Hussain I, Brennan A, Craggs M Sakakibara R et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain 2001; 124: 369-77.
24. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-407.
25. Stewart AL, Ware JE. Measuring functioning and well being: the medical outcomes study approach. London: Duke University Press, 1992.
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
27. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-73.
28. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J 1965; 14: 61-65.
29. Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C et al. The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996; 77: 554-62.
30. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 1996; 77: 805-12.
31. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-42.